Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. [electronic resource]
Producer: 20120815Description: 33-42 p. digitalISSN:- 1874-0758
- Administration, Oral
- Animals
- Antineoplastic Agents -- administration & dosage
- Biological Availability
- Caco-2 Cells
- Cyclin-Dependent Kinases -- antagonists & inhibitors
- Cytochrome P-450 Enzyme System -- drug effects
- Dogs
- Female
- Hepatocytes -- enzymology
- Heterocyclic Compounds, 4 or More Rings -- administration & dosage
- Humans
- Inhibitory Concentration 50
- Janus Kinase 2 -- antagonists & inhibitors
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Microsomes, Liver -- metabolism
- Rats
- Rats, Wistar
- Species Specificity
- Tissue Distribution
- fms-Like Tyrosine Kinase 3 -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.